HLTH:AU:AU-VanEck Global Healthcare Leaders ETF (AUD)

ETF | Others |

Last Closing

USD 11.37

Change

+0.05 (+0.44)%

Market Cap

USD 0.06B

Volume

403.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.53 (+0.53%)

USD 16.82B
IVV:AU iShares Core S&P 500 AUD

-0.03 (-0.05%)

USD 8.73B
VGS:AU Vanguard MSCI International Sh..

+0.08 (+0.06%)

USD 8.59B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.24 (+0.44%)

USD 6.70B
IOZ:AU Ishares Core S&P/Asx 200

+0.21 (+0.64%)

USD 6.18B
STW:AU SPDR® S&P/ASX 200 Fund

+0.49 (+0.67%)

USD 5.58B
NDQ:AU Betashares Nasdaq 100

+0.08 (+0.18%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.33 (+0.82%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.81 (+0.60%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

-0.38 (-0.09%)

USD 4.71B

ETFs Containing HLTH:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.50% 61% D- 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.50% 61% D- 55% F
Trailing 12 Months  
Capital Gain 16.86% 58% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.86% 58% F 56% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.20% 26% F 40% F
Dividend Return 0.51% 22% F 37% F
Total Return 0.31% 12% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 8.39% 64% D 93% A
Risk Adjusted Return 6.03% 19% F 39% F
Market Capitalization 0.06B 15% F 50% F

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.